UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?

UnitedHealth stock plunges 40% YTD—but $30M+ insider buys signal confidence. Is now the time for value investors to act?

May 22, 2025

Despite the healthcare sector's reputation for stability, UnitedHealth Group (NYSE: UNH) has recently faced significant market turbulence.

By mid-May 2025, the company's stock price had dropped over 40% year-to-date, raising concerns about its immediate future. However, substantial price declines in leading companies can create attractive investment opportunities. 

Adding to this attractiveness, significant share acquisitions by UnitedHealth's top executives suggest internal confidence despite market anxieties.

So if the insiders are putting their money into UnitedHealth Group’s future, should you?

Trump’s Final Reset

Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.

UnitedHealth's Plunge: A Silver Lining for Value Seekers?

UnitedHealth Group's stature as a global healthcare leader is undisputed. Yet, recent months have presented a stark contrast to its historical stability, with its stock experiencing a downturn.

While unsettling for some, this volatility can also create conditions in which a company's market price may diverge from its long-term intrinsic worth.

Such moments can warrant closer inspection for investors with a strategic, long-term perspective. Recently, substantial share purchases by UnitedHealth's most senior executives have added fuel to this signal for re-evaluation.

These actions, particularly when set against a backdrop of market pessimism, often signal the need for a deep-dive examination into a company's underlying fundamentals and prospects.

UnitedHealth's $30 Million+ Insider Vote of Confidence

Market participants often take notice when company insiders, particularly those in top leadership roles, make significant open-market purchases of their own company's stock.

Such has been the case at UnitedHealth Group in mid-May 2025. Stephen Hemsley, who returned to the CEO position, made a substantial personal investment, acquiring 86,700 shares on May 16, 2025, at an average price of $288.57 per share, totaling approximately $25 million.

On the same day, John Rex, the company’s President and CFO, purchased 17,175 shares at an average price of $291.11, an investment of roughly $5 million. Recent share acquisitions by directors John Noseworthy, Kristen Gil, and Timothy Flynn, occurring within days of these significant commitments, further reinforce them.

In financial markets, these types of insider transactions are often interpreted as powerful signals. They suggest that those with the most intimate knowledge of the company's operations, strategic direction, and internal forecasts believe the broader market may undervalue the stock.

Furthermore, such substantial personal investments underscore a conviction in the company's ability to navigate current challenges and achieve future growth, directly aligning the financial interests of these executives with those of all shareholders. Coming at a time when UnitedHealth’s shares were under considerable pressure, these multi-million dollar endorsements speak volumes about internal confidence.

As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever.

But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs…Paving the way for Elon Musk's secret master plan.

UnitedHealth's Fundamental Pillars of Strength

UnitedHealth Group's long-term investment appeal lies in its fundamental strengths. As a leading and diversified global healthcare enterprise, its business model centers on UnitedHealthcare, a major U.S. health insurer providing perceived long-term stability, and Optum, a rapidly growing health services arm leveraging technology and data analytics.

Optum's expansion in areas like value-based care drives UnitedHealth's growth. The company's strong financial profile includes $371.6 billion in 2023 revenue ($109.58 billion in Q1 2025) and an A+ credit rating.

UnitedHealth consistently returns capital to shareholders with an attractive dividend yield (around 2.67-2.9% due to a recent share price dip), a 15-year history of dividend increases (13.46% 3-year annualized growth), and a sustainable payout ratio (around 35% of earnings, 42-45% of cash flow), indicating potential for future growth.

Is UnitedHealth on Sale?

The significant recalibration in UnitedHealth Group's share price has naturally brought its valuation metrics into sharper focus. For investors, a key question is whether the current price reflects an attractive entry point. The forward price-to-earnings ratio (P/E) stood at approximately 10.75 to 12.22 in mid-May 2025, significantly below the company’s five-year average P/E of 25.60.

While various factors influence P/E ratios, including growth expectations and market sentiment, the current metrics, following a substantial price decline, may indicate that much of the recent negative news has been priced into the shares.

This scenario often attracts value-oriented investors who look for fundamentally sound companies trading at what they perceive to be a temporary discount.

UnitedHealth: Opportunity for the Patient Investor?

For investors considering UnitedHealth Group, the current terrain presents a complicated mixture of factors. Strong signals of insider confidence, reflected in substantial executive stock purchases, coincide with a period where the company's shares are trading at a valuation notably below historical norms.

These elements are set against the backdrop of a fundamentally sound business with market-leading positions, a diversified operational model via UnitedHealthcare and Optum, and a consistent commitment to shareholder returns through a growing dividend.

While near-term headwinds related to medical cost trends and regulatory scrutiny remain pertinent, UnitedHealth's proactive management strategies and inherent strengths provide a strong counter-narrative.

For those with a long-term investment horizon, the current market dislocation may offer a strategic opportunity to acquire shares in a premier healthcare enterprise at what could be perceived as a discounted price.

Written by Jeffrey Neal Johnson

Featured Articles:

He’s already IPO’d once – this time’s different

Spencer Rascoff grew Zillow from seed to IPO. But everyday investors couldn’t join until then, missing early gains. So he did things differently with Pacaso. They’ve made $110M+ in gross profits disrupting a $1.3T market. And after reserving the Nasdaq ticker PCSO, you can join for $2.80/share until 5/29.

This is a paid advertisement for Pacaso’s Regulation A offering. Please read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals. Under Regulation A+, a company has the ability to change its share price by up to 20%, without requalifying the offering with the SEC.

Copyright MarketBeat Media, LLC 2025
345 N Reid Place, Suite 620, Sioux Falls, SD 57103